# A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)

> **NCT06256523** · PHASE1,PHASE2 · COMPLETED · sponsor: **Gan and Lee Pharmaceuticals, USA** · enrollment: 72 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** GZR18
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06256523
- **Lead sponsor:** Gan and Lee Pharmaceuticals, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-29
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-09-28
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06256523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06256523, "A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06256523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*